These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

71 related articles for article (PubMed ID: 33783881)

  • 21. PD-(L)1 Inhibitors as Monotherapy for the First-Line Treatment of Non-Small-Cell Lung Cancer Patients with High PD-L1 Expression: A Network Meta-Analysis.
    Majem M; Cobo M; Isla D; Marquez-Medina D; Rodriguez-Abreu D; Casal-Rubio J; Bueno TM; Bernabé-Caro R; Parente DP; Ruiz-Gracia P; Arroyo MM; Paz-Ares L
    J Clin Med; 2021 Mar; 10(7):. PubMed ID: 33810441
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Invasive Fungal Diseases in Children with Hematological Malignancies Treated with Therapies That Target Cell Surface Antigens: Monoclonal Antibodies, Immune Checkpoint Inhibitors and CAR T-Cell Therapies.
    Kyriakidis I; Vasileiou E; Rossig C; Roilides E; Groll AH; Tragiannidis A
    J Fungi (Basel); 2021 Mar; 7(3):. PubMed ID: 33807678
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Value of the Lung Immune Prognostic Index in Patients with Non-Small Cell Lung Cancer Initiating First-Line Atezolizumab Combination Therapy: Subgroup Analysis of the IMPOWER150 Trial.
    Hopkins AM; Kichenadasse G; Abuhelwa AY; McKinnon RA; Rowland A; Sorich MJ
    Cancers (Basel); 2021 Mar; 13(5):. PubMed ID: 33803256
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Gustave Roussy Immune (GRIm)-Score Variation Is an Early-on-Treatment Biomarker of Outcome in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Treated with First-Line Pembrolizumab.
    Lenci E; Cantini L; Pecci F; Cognigni V; Agostinelli V; Mentrasti G; Lupi A; Ranallo N; Paoloni F; Rinaldi S; Nicolardi L; Caglio A; Aerts S; Cortellini A; Ficorella C; Chiari R; Di Maio M; Dingemans AC; Aerts JGJV; Berardi R
    J Clin Med; 2021 Mar; 10(5):. PubMed ID: 33801320
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A case of panuveitis and retinal vasculitis associated with pembrolizumab therapy for metastatic lung cancer.
    Kim KW; Kusuhara S; Tachihara M; Mimura C; Matsumiya W; Nakamura M
    Am J Ophthalmol Case Rep; 2021 Jun; 22():101072. PubMed ID: 33796799
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pembrolizumab plus eribulin in hormone-receptor-positive, HER2-negative, locally recurrent or metastatic breast cancer (KELLY): An open-label, multicentre, single-arm, phase Ⅱ trial.
    Pérez-García JM; Llombart-Cussac A; G Cortés M; Curigliano G; López-Miranda E; Alonso JL; Bermejo B; Calvo L; Carañana V; de la Cruz Sánchez S; M Vázquez R; Prat A; R Borrego M; Sampayo-Cordero M; Seguí-Palmer MÁ; Soberino J; Malfettone A; Schmid P; Cortés J
    Eur J Cancer; 2021 May; 148():382-394. PubMed ID: 33794440
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Complete metabolic response in patients with advanced nonsmall cell lung cancer with prolonged response to immune checkpoint inhibitor therapy.
    Ferdinandus J; Metzenmacher M; Kessler L; Umutlu L; Aigner C; Karl KO; Grünwald V; Eberhardt W; Fendler WP; Herrmann K; Faehling M; Christoph DC
    J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33789880
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Frequency of pre-treatment may not increase the immune-related adverse events of RCC patients treated with nivolumab.
    Mizutani K; Ito T; Takahara K; Ando R; Ishihara T; Yasui T; Shiroki R; Miyake H; Koie T
    Medicine (Baltimore); 2021 Apr; 100(13):e25402. PubMed ID: 33787647
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical recommendations for perioperative immunotherapy-induced adverse events in patients with non-small cell lung cancer.
    Ni J; Huang M; Zhang L; Wu N; Bai CX; Chen LA; Liang J; Liu Q; Wang J; Wu YL; Zhang FC; Zhang SY; Chen C; Chen J; Fang WT; Gao SG; Hu J; Jiang T; Li SQ; Li HC; Liao YD; Liu Y; Liu DR; Liu HX; Liu JY; Liu LX; Wang MZ; Wang CL; Yang F; Yang Y; Zhang LJ; Zhi XY; Zhong WZ; Guan YZ; Guo XX; He CX; Li SL; Li Y; Liang NX; Lu FL; Lv C; Lv W; Si XY; Tan FW; Wang HP; Wang JS; Yan S; Yang HX; Zhu HJ; Zhuang JL; Zhuo ML
    Thorac Cancer; 2021 May; 12(9):1469-1488. PubMed ID: 33787090
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Treatment of corticosteroid refractory immune checkpoint inhibitor myocarditis with Infliximab: a case series.
    Zhang RS; Padegimas A; Murphy KM; Evans PT; Peters CJ; Domenico CM; Vidula MK; Mather PJ; Cevasco M; Cohen RB; Carver JR; O'Quinn RP
    Cardiooncology; 2021 Mar; 7(1):13. PubMed ID: 33785062
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Drug-related exanthema under immunotherapy and targeted oncological therapy].
    Ziemer M; Livingstone E
    Dermatologie (Heidelb); 2024 Jun; 75(6):440-450. PubMed ID: 38772932
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Autoimmune bullous dermatoses in cancer patients treated by immunotherapy: a literature review and Italian multicentric experience.
    Merli M; Accorinti M; Romagnuolo M; Marzano A; Di Zenzo G; Moro F; Antiga E; Maglie R; Cozzani E; Parodi A; Gasparini G; Sollena P; De Simone C; Caproni M; Pisano L; Fattore D; Balestri R; Sena P; Vezzoli P; Teoli M; Ardigò M; Vassallo C; Michelerio A; Satta RR; Dika E; Melotti B; Ribero S; Quaglino P
    Front Med (Lausanne); 2023; 10():1208418. PubMed ID: 37547602
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A Review of Bullous Dermatologic Adverse Events Associated with Anti-Cancer Therapy.
    Parisi R; Shah H; Shear NH; Ziv M; Markova A; Dodiuk-Gad RP
    Biomedicines; 2023 Jan; 11(2):. PubMed ID: 36830860
    [TBL] [Abstract][Full Text] [Related]  

  • 34. What's new in the pathogeneses and triggering factors of bullous pemphigoid.
    Ujiie H
    J Dermatol; 2023 Feb; 50(2):140-149. PubMed ID: 36412277
    [TBL] [Abstract][Full Text] [Related]  

  • 35. High Grade Dermatologic Adverse Events Associated With Immune Checkpoint Blockade for Cancer.
    Kuo AM; Markova A
    Front Med (Lausanne); 2022; 9():898790. PubMed ID: 35770005
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Contribution of the Skin-Gut Axis to Immune-Related Adverse Events with Multi-System Involvement.
    Kuo AM; Kraehenbuehl L; King S; Leung DYM; Goleva E; Moy AP; Lacouture ME; Shah NJ; Faleck DM
    Cancers (Basel); 2022 Jun; 14(12):. PubMed ID: 35740660
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dermatologic immune-related adverse events: The toxicity spectrum and recommendations for management.
    Apalla Z; Rapoport B; Sibaud V
    Int J Womens Dermatol; 2021 Dec; 7(5Part A):625-635. PubMed ID: 35005180
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical, biological and histological characteristics of bullous pemphigoid associated with anti-PD-1/PD-L1 therapy: A national retrospective study.
    Juzot C; Sibaud V; Amatore F; Mansard S; Seta V; Jeudy G; Pham-Ledard A; Benzaquen M; Peuvrel L; Le Corre Y; Lesage C; Viguier M; Baroudjian B; Dréno B; Quéreux G
    J Eur Acad Dermatol Venereol; 2021 Aug; 35(8):e511-e514. PubMed ID: 33783881
    [No Abstract]   [Full Text] [Related]  

  • 39. Bullous disorders associated with anti-PD-1 and anti-PD-L1 therapy: A retrospective analysis evaluating the clinical and histopathologic features, frequency, and impact on cancer therapy.
    Siegel J; Totonchy M; Damsky W; Berk-Krauss J; Castiglione F; Sznol M; Petrylak DP; Fischbach N; Goldberg SB; Decker RH; Stamatouli AM; Hafez N; Glusac EJ; Tomayko MM; Leventhal JS
    J Am Acad Dermatol; 2018 Dec; 79(6):1081-1088. PubMed ID: 30025829
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A review of bullous pemphigoid associated with PD-1 and PD-L1 inhibitors.
    Lopez AT; Khanna T; Antonov N; Audrey-Bayan C; Geskin L
    Int J Dermatol; 2018 Jun; 57(6):664-669. PubMed ID: 29630716
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.